Citicoline
- Generic Name
- Citicoline
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C14H26N4O11P2
- CAS Number
- 987-78-0
- Unique Ingredient Identifier
- 536BQ2JVC7
- Background
Citicoline is a donor of choline in biosynthesis of choline-containing phosphoglycerides. It has been investigated for the treatment, supportive care, and diagnosis of Mania, Stroke, Hypomania, Cocaine Abuse, and Bipolar Disorder, among others.
- Indication
主要用于急性颅脑外伤和脑手术后的意识障碍，以及脑卒中而致偏瘫的患者；也用于耳鸣及神经性耳聋、急性中毒、感染、大面积脑梗死所致的昏迷和意识障碍、帕金森病、急性胰腺炎；对缺血性脑血管病和血管性痴呆也有一定疗效,但对颅内出血引起的意识障碍效果较差。
- Associated Conditions
- Degenerative Brain Disorder, Parkinsonian Syndromes
- Associated Therapies
- -
Supplemental Citicoline Administration to Reduce Lung Injury Efficacy Trial (SCARLET)
- First Posted Date
- 2023-05-31
- Last Posted Date
- 2023-10-25
- Lead Sponsor
- Ohio State University
- Target Recruit Count
- 80
- Registration Number
- NCT05881135
- Locations
- 🇺🇸
The Ohio State Wexner Medical Center, Columbus, Ohio, United States
The Impact of Air Travel on Passenger Cognitive Functions
- Conditions
- Interventions
- Drug: Melatonin 5 mgDrug: CiticolineDrug: Cytochrome C6Drug: Sodium Chloride Oral ProductDrug: Potassium Chloride Oral ProductDrug: Sodium Citrate Oral ProductDrug: Dextrose Oral Tablet, ChewableDrug: Domperidone Oral ProductDrug: SimethiconeDrug: Acetylsalicylic acidDrug: Magnesium hydroxideDrug: Probiotic Formula
- First Posted Date
- 2021-03-17
- Last Posted Date
- 2021-03-17
- Lead Sponsor
- Dinara Zhumanbayeva
- Target Recruit Count
- 50
- Registration Number
- NCT04802785
Citicoline Concentration in Human Vitreous
- First Posted Date
- 2019-07-01
- Last Posted Date
- 2019-07-01
- Lead Sponsor
- Istituto di Ricerca Neuroftalmologia S.r.l.
- Target Recruit Count
- 26
- Registration Number
- NCT04003090
- Locations
- 🇮🇹
Fondazione G.B. Bietti- IRCCS, Roma, Italy
Citicoline as Neuroprotector in Preterm
- First Posted Date
- 2019-05-29
- Last Posted Date
- 2019-05-29
- Lead Sponsor
- Sherief Abd-Elsalam
- Target Recruit Count
- 40
- Registration Number
- NCT03966170
- Locations
- 🇪🇬
Sherief Abd-Elsalam, Tanta, Egypt
Citicoline as Neuroprotector in Neonates Exposed to Hypoxia
- First Posted Date
- 2019-05-14
- Last Posted Date
- 2019-05-29
- Lead Sponsor
- Sherief Abd-Elsalam
- Target Recruit Count
- 40
- Registration Number
- NCT03949049
- Locations
- 🇪🇬
Sherief Abd-Elsalam, Cairo, Egypt
Role of Citicoline in Treatment of Newborns With Hypoxic Ischemic Encephalopathy
- First Posted Date
- 2017-06-09
- Last Posted Date
- 2017-06-09
- Lead Sponsor
- Armed Forces Hospital, Pakistan
- Target Recruit Count
- 50
- Registration Number
- NCT03181646
- Locations
- 🇵🇰
Department of Pediatrics, Rawalpindi, Punjab, Pakistan
Ramelteon and Citicoline for Delirium
- First Posted Date
- 2016-07-21
- Last Posted Date
- 2017-11-09
- Lead Sponsor
- University of Texas Southwestern Medical Center
- Registration Number
- NCT02840591
- Locations
- 🇺🇸
The University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, United States
CDP-choline Treatment in ATS Users
- Conditions
- Interventions
- First Posted Date
- 2015-12-15
- Last Posted Date
- 2022-08-01
- Lead Sponsor
- Ewha Womans University Mokdong Hospital
- Target Recruit Count
- 160
- Registration Number
- NCT02630069
- Locations
- 🇰🇷
Ewha Womans University Mokdong Hospital, Seoul, Korea, Republic of
Citicoline for Alcohol Dependence
- First Posted Date
- 2014-02-28
- Last Posted Date
- 2018-07-24
- Lead Sponsor
- University of Texas Southwestern Medical Center
- Target Recruit Count
- 62
- Registration Number
- NCT02074735
- Locations
- 🇺🇸
The University of Texas Southwestern Medical CEnter, Dallas, Texas, United States
A Pilot Trial of Citicoline in Individuals With Mild Traumatic Brain Injury (mTBI)
- First Posted Date
- 2012-05-04
- Last Posted Date
- 2014-04-23
- Lead Sponsor
- Mclean Hospital
- Registration Number
- NCT01591759
- Locations
- 🇺🇸
McLean Hospital Brain Imaging Center, Belmont, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.